137,500 Shares in Avadel Pharmaceuticals PLC. $AVDL Purchased by Schulhoff & Co. Inc.

Schulhoff & Co. Inc. bought a new position in Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 137,500 shares of the company’s stock, valued at approximately $2,100,000.

Other institutional investors also recently made changes to their positions in the company. Brandes Investment Partners LP raised its position in shares of Avadel Pharmaceuticals by 14.5% during the 2nd quarter. Brandes Investment Partners LP now owns 6,487,642 shares of the company’s stock worth $57,416,000 after purchasing an additional 820,467 shares during the period. Two Seas Capital LP grew its stake in Avadel Pharmaceuticals by 24.4% during the 2nd quarter. Two Seas Capital LP now owns 6,155,074 shares of the company’s stock worth $54,472,000 after buying an additional 1,208,625 shares during the last quarter. Vanguard Group Inc. increased its position in Avadel Pharmaceuticals by 0.8% in the third quarter. Vanguard Group Inc. now owns 5,606,282 shares of the company’s stock worth $85,608,000 after buying an additional 42,023 shares during the period. Geode Capital Management LLC lifted its stake in Avadel Pharmaceuticals by 82.3% in the second quarter. Geode Capital Management LLC now owns 2,169,018 shares of the company’s stock valued at $19,198,000 after buying an additional 979,422 shares during the last quarter. Finally, Kennedy Capital Management LLC boosted its holdings in shares of Avadel Pharmaceuticals by 30.1% during the second quarter. Kennedy Capital Management LLC now owns 981,271 shares of the company’s stock valued at $8,684,000 after acquiring an additional 227,228 shares during the period. 69.19% of the stock is owned by institutional investors.

Avadel Pharmaceuticals Stock Down 1.1%

AVDL stock opened at $21.39 on Monday. The company has a 50-day simple moving average of $21.51 and a 200 day simple moving average of $18.73. Avadel Pharmaceuticals PLC. has a fifty-two week low of $6.38 and a fifty-two week high of $23.57.

Analyst Ratings Changes

Several research firms have recently commented on AVDL. Weiss Ratings restated a “sell (d-)” rating on shares of Avadel Pharmaceuticals in a research report on Monday, December 29th. Wells Fargo & Company boosted their target price on shares of Avadel Pharmaceuticals from $20.00 to $22.50 and gave the company an “equal weight” rating in a research note on Thursday, November 20th. UBS Group lowered shares of Avadel Pharmaceuticals to a “neutral” rating in a research note on Tuesday, October 28th. Finally, Zacks Research raised Avadel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 6th. One analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Avadel Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $20.00.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc is a global specialty biopharmaceutical company focused on developing and delivering treatments for rare diseases and central nervous system disorders. Headquartered in Dublin, Ireland, with operations in the United States, Avadel’s portfolio centers on sleep disorder therapeutics, including its flagship low-sodium oxybate product, XYWAV, which is approved in the U.S. for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. The company is also advancing FT218, a once-nightly formulation of sodium oxybate, currently under regulatory review for narcolepsy management.

Formed through a rebranding of Flamel Technologies in 2016 and a strategic shift toward rare disease drug development, Avadel has built its R&D capabilities around improving patient compliance and reducing daily sodium exposure compared to traditional therapies.